scholarly article | Q13442814 |
P356 | DOI | 10.1080/03007995.2016.1210107 |
P698 | PubMed publication ID | 27388660 |
P2093 | author name string | Stephen S Lane | |
Edward J Holland | |||
Aparna Raychaudhuri | |||
Kenneth Sall | |||
Amir Shojaei | |||
Walter O Whitley | |||
Steven Y Zhang | |||
P2860 | cites work | Lifitegrast, a Novel Integrin Antagonist for Treatment of Dry Eye Disease | Q26774853 |
Associations between signs and symptoms of dry eye disease: a systematic review | Q26781979 | ||
The pharmacologic assessment of a novel lymphocyte function-associated antigen-1 antagonist (SAR 1118) for the treatment of keratoconjunctivitis sicca in dogs | Q34165372 | ||
Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study | Q34493904 | ||
Dry eye as a mucosal autoimmune disease | Q34647761 | ||
Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study | Q36877000 | ||
Dry eye disease: an immune-mediated ocular surface disorder | Q36916372 | ||
Corneal inflammation is inhibited by the LFA-1 antagonist, lifitegrast (SAR 1118) | Q40356553 | ||
Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study | Q42708147 | ||
Ocular surface APCs are necessary for autoreactive T cell-mediated experimental autoimmune lacrimal keratoconjunctivitis. | Q50994458 | ||
P407 | language of work or name | English | Q1860 |
P921 | main subject | eye disease | Q3041498 |
lifitegrast | Q23044263 | ||
P304 | page(s) | 1-24 | |
P577 | publication date | 2016-07-08 | |
P1433 | published in | Current Medical Research and Opinion | Q5195063 |
P1476 | title | Lifitegrast clinical efficacy for treatment of signs and symptoms of dry eye disease across three randomized controlled trials |
Q58742470 | Contribution of HIV Infection, AIDS, and Antiretroviral Therapy to Exocrine Pathogenesis in Salivary and Lacrimal Glands |
Q48095233 | Current Anti-Integrin Therapy for Ocular Disease |
Q39025675 | LFA-1/ICAM-1 Interaction as a Therapeutic Target in Dry Eye Disease |
Q39069560 | Lifitegrast Ophthalmic Solution 5%: A Review in Dry Eye Disease |
Q64106425 | Longitudinal changes in dry eye symptoms and signs following lifitegrast therapy and relationship to tear osmolarity |
Q47268214 | Ocular Distribution and Pharmacokinetics of Lifitegrast in Pigmented Rabbits and Mass Balance in Beagle Dogs |
Q58694745 | Safety and efficacy of lifitegrast 5% ophthalmic solution in contact lens discomfort |
Q92236526 | Six months' treatment with lifitegrast in patients with moderate-to-severe symptomatic dry eye: a retrospective chart review |
Search more.